March 27, 2017 / 8:31 PM / 4 months ago

BRIEF-FDA approves Tesaro's ovarian cancer drug

1 Min Read

March 27 (Reuters) - U.S. FDA:

* U.S. FDA granted the approval of Zejula to Tesaro Inc

* U.S. FDA - FDA granted the application fast track, priority review and breakthrough therapy designations

* U.S. FDA - Zejula also received orphan drug designation specifically for its use in treating recurrent epithelial ovarian cancer

* U.S. FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below